Details of the Drug Combination

General Information of Drug Combination (ID: DCFF9VM)

• Drug Combination Name: cycloheximide + Naltrexone
• Indication: Hepatoblastoma; Status: Investigative [1]
• Component Drugs:
  cycloheximide (DMGDA3C): Small molecular drug
  Naltrexone (DMUL45H): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: HB3
  Zero Interaction Potency (ZIP) Score: 3.795
  Bliss Independence Score: 3.293
  Loewe Additivity Score: 3.863
  LHighest Single Agent (HSA) Score: 7.115

Molecular Interaction Atlas of This Drug Combination

Indication(s) of cycloheximide

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[2]

cycloheximide Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[15]

cycloheximide Interacts with 78 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Expression	[16]
ATP-binding cassette sub-family C member 3 (ABCC3)	OTC3IJV4	MRP3_HUMAN	Increases Expression	[8]
ATP-binding cassette sub-family C member 5 (ABCC5)	OT34G4US	MRP5_HUMAN	Decreases Expression	[8]
Transforming acidic coiled-coil-containing protein 1 (TACC1)	OTGX20TE	TACC1_HUMAN	Increases Expression	[8]
Receptor tyrosine-protein kinase erbB-2 (ERBB2)	OTOAUNCK	ERBB2_HUMAN	Decreases Expression	[8]
Insulin-like growth factor-binding protein 4 (IGFBP4)	OT2HZRBD	IBP4_HUMAN	Increases Expression	[8]
CCN family member 3 (CCN3)	OTOW5YL4	CCN3_HUMAN	Increases Expression	[8]
Dynamin-1-like protein (DNM1L)	OTXK1Q1G	DNM1L_HUMAN	Increases Expression	[17]
Apoptotic protease-activating factor 1 (APAF1)	OTJWIVY0	APAF_HUMAN	Decreases Expression	[17]
Glycosylphosphatidylinositol anchor attachment 1 protein (GPAA1)	OTWVRR35	GPAA1_HUMAN	Increases Expression	[17]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1)	OTM0GDTP	IF2A_HUMAN	Increases Expression	[17]
Glia-derived nexin (SERPINE2)	OTYF5340	GDN_HUMAN	Increases Expression	[17]
ETS domain-containing protein Elk-1 (ELK1)	OTH9MXD6	ELK1_HUMAN	Increases Expression	[17]
CCN family member 2 (CCN2)	OTC39NSU	CCN2_HUMAN	Increases Expression	[17]
Kappa-type opioid receptor (OPRK1)	OTXCZF4L	OPRK_HUMAN	Increases Expression	[17]
Collagenase 3 (MMP13)	OTY8BZIE	MMP13_HUMAN	Increases Expression	[17]
Heterogeneous nuclear ribonucleoprotein H2 (HNRNPH2)	OTMGP4J7	HNRH2_HUMAN	Increases Expression	[17]
Single-stranded DNA-binding protein, mitochondrial (SSBP1)	OTH2PZWH	SSBP_HUMAN	Increases Expression	[17]
Mitogen-activated protein kinase 7 (MAPK7)	OTF7H7L7	MK07_HUMAN	Increases Expression	[17]
Pappalysin-1 (PAPPA)	OTTTG9PG	PAPP1_HUMAN	Increases Expression	[17]
SERTA domain-containing protein 2 (SERTAD2)	OTYIG6TP	SRTD2_HUMAN	Increases Expression	[17]
Next to BRCA1 gene 1 protein (NBR1)	OTVRL7J9	NBR1_HUMAN	Increases Expression	[17]
5'-3' exonuclease PLD3 (PLD3)	OTL07SP2	PLD3_HUMAN	Increases Expression	[17]
Synaptopodin (SYNPO)	OTICDJAB	SYNPO_HUMAN	Increases Expression	[17]
Transmembrane protein 263 (TMEM263)	OTO1RSTS	TM263_HUMAN	Increases Expression	[17]
Alpha-N-acetylneuraminide alpha-2,8-sialyltransferase (ST8SIA1)	OTGND2YZ	SIA8A_HUMAN	Increases Expression	[17]
Sororin (CDCA5)	OTZLCQ5U	CDCA5_HUMAN	Increases Expression	[17]
Retinoic acid receptor responder protein 2 (RARRES2)	OT1BJE8K	RARR2_HUMAN	Increases Expression	[17]
Solute carrier family 22 member 4 (SLC22A4)	OT4LOVI9	S22A4_HUMAN	Increases Expression	[17]
CDC42 small effector protein 2 (CDC42SE2)	OT8SG9I1	C42S2_HUMAN	Increases Expression	[17]
Myotubularin-related protein 7 (MTMR7)	OT47NVYM	MTMR7_HUMAN	Increases Expression	[17]
Small ribosomal subunit protein uS7m (MRPS7)	OT57AX7G	RT07_HUMAN	Decreases Expression	[17]
Amino acid transporter heavy chain SLC3A2 (SLC3A2)	OTBR33M9	4F2_HUMAN	Increases Expression	[18]
Tumor protein p53-inducible protein 11 (TP53I11)	OTFPDYZU	P5I11_HUMAN	Decreases Expression	[19]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[20]
Proepiregulin (EREG)	OTRM4NQY	EREG_HUMAN	Increases Expression	[21]
CASP8 and FADD-like apoptosis regulator (CFLAR)	OTX14BAS	CFLAR_HUMAN	Decreases Expression	[22]
Autophagy-related protein 13 (ATG13)	OTYMHNEJ	ATG13_HUMAN	Decreases Expression	[11]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A)	OTYG179K	PR15A_HUMAN	Decreases Expression	[23]
Mitochondrial uncoupling protein 4 (SLC25A27)	OTSBOPGD	UCP4_HUMAN	Increases Expression	[24]
Protein c-Fos (FOS)	OTJBUVWS	FOS_HUMAN	Increases Expression	[25]
Transforming growth factor beta-1 proprotein (TGFB1)	OTV5XHVH	TGFB1_HUMAN	Decreases Activity	[26]
Superoxide dismutase , mitochondrial (SOD2)	OTIWXGZ9	SODM_HUMAN	Increases Expression	[27]
Transcription factor AP-2-alpha (TFAP2A)	OTMYT3NK	AP2A_HUMAN	Decreases Stability	[28]
Beta-2 adrenergic receptor (ADRB2)	OTSDOX4Q	ADRB2_HUMAN	Increases Expression	[29]
Rho-related GTP-binding protein RhoC (RHOC)	OTOLE1FT	RHOC_HUMAN	Decreases Expression	[30]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[31]
Intestinal-type alkaline phosphatase (ALPI)	OTTQ468O	PPBI_HUMAN	Decreases Activity	[32]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Increases Expression	[33]
E3 SUMO-protein ligase EGR2 (EGR2)	OTAVQ78J	EGR2_HUMAN	Increases Expression	[34]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Increases Expression	[33]
C-C motif chemokine 5 (CCL5)	OTSCA5CK	CCL5_HUMAN	Increases Expression	[33]
Nuclear factor NF-kappa-B p105 subunit (NFKB1)	OTNRRD8I	NFKB1_HUMAN	Increases Expression	[33]
Receptor tyrosine-protein kinase erbB-3 (ERBB3)	OTRSST0A	ERBB3_HUMAN	Decreases Expression	[21]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Increases Phosphorylation	[35]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Increases Phosphorylation	[35]
Retinoblastoma-like protein 1 (RBL1)	OTDEBFYC	RBL1_HUMAN	Decreases Expression	[36]
Protein PML (PML)	OT6SM2GD	PML_HUMAN	Decreases Degradation	[37]
Pro-adrenomedullin (ADM)	OT7T0TA4	ADML_HUMAN	Increases Expression	[38]
Receptor-type tyrosine-protein kinase FLT3 (FLT3)	OTMSRYMK	FLT3_HUMAN	Decreases Expression	[39]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Decreases Expression	[40]
Cyclin-dependent kinase inhibitor 2A (CDKN2A)	OTN0ZWAE	CDN2A_HUMAN	Increases Expression	[41]
E3 ubiquitin-protein ligase RNF4 (RNF4)	OTCMXQRE	RNF4_HUMAN	Decreases Expression	[42]
Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17)	OTTM6KRB	ADA17_HUMAN	Decreases Stability	[43]
Heat shock factor protein 1 (HSF1)	OTYNJ4KP	HSF1_HUMAN	Decreases Activity	[44]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Affects Localization	[45]
Tight junction protein ZO-1 (TJP1)	OTBDCUPK	ZO1_HUMAN	Decreases Expression	[46]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Increases Expression	[47]
Protein NDRG1 (NDRG1)	OTVO66BO	NDRG1_HUMAN	Decreases Expression	[48]
Type II iodothyronine deiodinase (DIO2)	OTGPNSLH	IOD2_HUMAN	Decreases Activity	[49]
Transcription termination factor 3, mitochondrial (MTERF3)	OTVE8W7X	MTEF3_HUMAN	Decreases Expression	[50]
Endothelial PAS domain-containing protein 1 (EPAS1)	OTRE3O8U	EPAS1_HUMAN	Decreases Expression	[51]
Repressor of RNA polymerase III transcription MAF1 homolog (MAF1)	OTKB0N8Q	MAF1_HUMAN	Increases Degradation	[52]
D-ribitol-5-phosphate cytidylyltransferase (CRPPA)	OTC85K8Q	ISPD_HUMAN	Affects Response To Substance	[14]
Rab9 effector protein with kelch motifs (RABEPK)	OTCZSREH	RABEK_HUMAN	Affects Response To Substance	[14]
Kremen protein 1 (KREMEN1)	OTGJFSAC	KREM1_HUMAN	Affects Response To Substance	[14]
Unconventional myosin-Id (MYO1D)	OTP2RGPN	MYO1D_HUMAN	Affects Response To Substance	[14]
Cation channel sperm-associated protein 4 (CATSPER4)	OTXJ4E8J	CTSR4_HUMAN	Affects Response To Substance	[14]

Indication(s) of Naltrexone

Disease Entry	ICD 11	Status	REF
Alcohol dependence	6C40.2	Approved	[3]
Chronic alcoholism	6C40.2Z	Approved	[4]
Crohn disease	DD70	Approved	[5]
Gastroparesis	DA41.00	Approved	[5]
Inflammatory bowel disease	DD72	Approved	[5]
Obesity	5B81	Approved	[5]
Ulcerative colitis	DD71	Approved	[5]
Human immunodeficiency virus infection	1C62	Phase 4	[6]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[7]
Chronic pain	MG30	Investigative	[5]

Naltrexone Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Opioid receptor (OPR)	TTN4QDT	NOUNIPROTAC	Antagonist	[53]

Naltrexone Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Metabolism	[54]

Naltrexone Interacts with 8 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Follitropin subunit beta (FSHB)	OTGLS283	FSHB_HUMAN	Increases Expression	[55]
Lutropin subunit beta (LHB)	OT5GBOVJ	LSHB_HUMAN	Increases Expression	[55]
Mu-type opioid receptor (OPRM1)	OT16AAT8	OPRM_HUMAN	Affects Response To Substance	[53]
Mu-type opioid receptor (OPRM1)	OT16AAT8	OPRM_HUMAN	Increases Response	[53]
Sodium-dependent dopamine transporter (SLC6A3)	OT39XG28	SC6A3_HUMAN	Affects Response To Substance	[56]
Gamma-aminobutyric acid receptor subunit beta-2 (GABRB2)	OTAOZIGX	GBRB2_HUMAN	Affects Response To Substance	[57]
D(2) dopamine receptor (DRD2)	OTBLXKEG	DRD2_HUMAN	Affects Response To Substance	[57]
Gamma-aminobutyric acid receptor subunit alpha-6 (GABRA6)	OTX4UC3O	GBRA6_HUMAN	Affects Response To Substance	[57]

References

• [1] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5433).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 074918.
• [5] Naltrexone FDA Label
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1639).
• [7] ClinicalTrials.gov (NCT04365985) Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19. U.S. National Institutes of Health.
• [8] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [9] Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells. Endocrinology. 2006 Aug;147(8):3843-50.
• [10] Inhibition of thymidine phosphorylase expression by Hsp90 inhibitor potentiates the cytotoxic effect of salinomycin in human non-small-cell lung cancer cells. Toxicology. 2019 Apr 1;417:54-63.
• [11] Suppressed translation and ULK1 degradation as potential mechanisms of autophagy limitation under prolonged starvation. Autophagy. 2016 Nov;12(11):2085-2097. doi: 10.1080/15548627.2016.1226733. Epub 2016 Sep 14.
• [12] Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase. Chem Biol Interact. 2022 Jun 1;360:109938. doi: 10.1016/j.cbi.2022.109938. Epub 2022 Apr 12.
• [13] Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1alpha protein by the oxidative stressor arsenite. J Biol Chem. 2001 Dec 21;276(51):48066-76. doi: 10.1074/jbc.M106282200. Epub 2001 Oct 18.
• [14] Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study. Environ Health Perspect. 2015 May;123(5):458-66. doi: 10.1289/ehp.1408775. Epub 2015 Jan 13.
• [15] Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
• [16] A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line. Mol Pharmacol. 1995 Oct;48(4):682-9.
• [17] Comparative analysis of AhR-mediated TCDD-elicited gene expression in human liver adult stem cells. Toxicol Sci. 2009 Nov;112(1):229-44.
• [18] Aryl hydrocarbon receptor-dependent up-regulation of the heterodimeric amino acid transporter LAT1 (SLC7A5)/CD98hc (SLC3A2) by diesel exhaust particle extract in human bronchial epithelial cells. Toxicol Appl Pharmacol. 2016 Jan 1;290:74-85.
• [19] Possible roles of a tumor suppressor gene PIG11 in hepatocarcinogenesis and As2O3-induced apoptosis in liver cancer cells. J Gastroenterol. 2009;44(5):460-9. doi: 10.1007/s00535-009-0030-1. Epub 2009 Apr 1.
• [20] Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst. 2004 Dec 1;96(23):1769-80. doi: 10.1093/jnci/djh322.
• [21] The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced. Mol Cell Biochem. 2004 May;260(1-2):129-35. doi: 10.1023/b:mcbi.0000026063.96267.98.
• [22] Inhibition of phosphatidylinositol 3-kinase sensitizes vascular endothelial cells to cytokine-initiated cathepsin-dependent apoptosis. J Biol Chem. 2003 Jun 6;278(23):21295-306. doi: 10.1074/jbc.M212837200. Epub 2003 Mar 27.
• [23] Chronic oxidative stress promotes GADD34-mediated phosphorylation of the TAR DNA-binding protein TDP-43, a modification linked to neurodegeneration. J Biol Chem. 2018 Jan 5;293(1):163-176. doi: 10.1074/jbc.M117.814111. Epub 2017 Nov 6.
• [24] Transcriptional regulation of UCP4 by NF-kappaB and its role in mediating protection against MPP+ toxicity. Free Radic Biol Med. 2010 Jul 15;49(2):192-204. doi: 10.1016/j.freeradbiomed.2010.04.002. Epub 2010 Apr 9.
• [25] Induction of c-fos proto-oncogene in mesangial cells by cadmium. J Biol Chem. 1998 Jan 2;273(1):73-9. doi: 10.1074/jbc.273.1.73.
• [26] Identification and Profiling of Environmental Chemicals That Inhibit the TGF/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11.
• [27] IkappaBalpha (inhibitory kappaBalpha) identified as labile repressor of MnSOD (manganese superoxide dismutase) expression. Biochem J. 2004 Dec 15;384(Pt 3):543-9. doi: 10.1042/BJ20040714.
• [28] Linc-ROR drive adriamycin resistance by targeting AP-2/Wnt/-catenin axis in hepatocellular carcinoma. Cell Biol Toxicol. 2023 Aug;39(4):1735-1752. doi: 10.1007/s10565-022-09777-3. Epub 2022 Dec 28.
• [29] Dual regulation of 2-adrenoceptor messenger RNA expression in human lung fibroblasts by 2-cAMP signaling; delayed upregulated inhibitors oppose a rapid in onset, direct stimulation of gene expression. Naunyn Schmiedebergs Arch Pharmacol. 2014 Jul;387(7):649-57. doi: 10.1007/s00210-014-0971-7. Epub 2014 Apr 8.
• [30] RNF168 suppresses the cancer stem cell-like traits of nonsmall cell lung cancer cells by mediating RhoC ubiquitination. Environ Toxicol. 2022 Mar;37(3):603-611. doi: 10.1002/tox.23428. Epub 2021 Dec 7.
• [31] Inhibition of breast cancer cell growth and induction of cell death by 1,1-bis(3'-indolyl)methane (DIM) and 5,5'-dibromoDIM. Cancer Lett. 2006 May 18;236(2):198-212. doi: 10.1016/j.canlet.2005.05.036. Epub 2005 Jul 26.
• [32] Deoxynivalenol affects in vitro intestinal epithelial cell barrier integrity through inhibition of protein synthesis. Toxicol Appl Pharmacol. 2010 Jun 15;245(3):291-8. doi: 10.1016/j.taap.2010.03.012. Epub 2010 Apr 1.
• [33] The synthetic bile acid-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide suppresses TNF-induced liver injury. J Hepatol. 2011 Apr;54(4):674-84. doi: 10.1016/j.jhep.2010.07.028. Epub 2010 Sep 27.
• [34] Redox-sensitive regulation of gene expression in human primary macrophages exposed to inorganic arsenic. J Cell Biochem. 2009 Jun 1;107(3):537-47. doi: 10.1002/jcb.22155.
• [35] Receptors for bitter, sweet and umami taste couple to inhibitory G protein signaling pathways. Eur J Pharmacol. 2004 Apr 12;489(3):139-49. doi: 10.1016/j.ejphar.2004.03.004.
• [36] Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology. 2010 May;138(5):1920-30. doi: 10.1053/j.gastro.2010.01.007. Epub 2010 Jan 25.
• [37] Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML. Toxicol Appl Pharmacol. 2015 Sep 15;287(3):191-201. doi: 10.1016/j.taap.2015.05.018. Epub 2015 Jun 3.
• [38] Induction of adrenomedullin during hypoxia in cultured human glioblastoma cells. J Neurochem. 2000 Nov;75(5):1826-33. doi: 10.1046/j.1471-4159.2000.0751826.x.
• [39] Arsenic trioxide induces autophagic degradation of the FLT3-ITD mutated protein in FLT3-ITD acute myeloid leukemia cells. J Cancer. 2020 Mar 13;11(12):3476-3482. doi: 10.7150/jca.29751. eCollection 2020.
• [40] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [41] 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) exposure of normal human dermal fibroblasts results in AhR-dependent and -independent changes in gene expression. Toxicol Appl Pharmacol. 2007 Apr 1;220(1):9-17. doi: 10.1016/j.taap.2006.12.002. Epub 2006 Dec 15.
• [42] Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies. Mol Biol Cell. 2010 Dec;21(23):4227-39. doi: 10.1091/mbc.E10-05-0449. Epub 2010 Oct 13.
• [43] Antiviral Potential of Small Molecules Cordycepin, Thymoquinone, and N6, N6-Dimethyladenosine Targeting SARS-CoV-2 Entry Protein ADAM17. Molecules. 2022 Dec 19;27(24):9044. doi: 10.3390/molecules27249044.
• [44] A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
• [45] Inactivation of IkappaB contributes to transcriptional activation of spermidine/spermine N(1)-acetyltransferase. Mol Carcinog. 2006 Sep;45(9):685-93. doi: 10.1002/mc.20239.
• [46] Effect of cytokines on ICAM-1 and ZO-1 expression on human airway epithelial cells. Cell Biol Int. 2005 Sep;29(9):768-77. doi: 10.1016/j.cellbi.2005.05.002.
• [47] Dexamethasone suppresses apoptosis in a human gastric cancer cell line through modulation of bcl-x gene expression. FEBS Lett. 1997 Sep 22;415(1):11-5. doi: 10.1016/s0014-5793(97)01083-1.
• [48] NDRG1 inhibition sensitizes osteosarcoma cells to combretastatin A-4 through targeting autophagy. Cell Death Dis. 2017 Sep 14;8(9):e3048. doi: 10.1038/cddis.2017.438.
• [49] The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line. J Biol Chem. 2001 Aug 10;276(32):30183-7. doi: 10.1074/jbc.C100325200. Epub 2001 Jun 25.
• [50] MTERF3 contributes to MPP+-induced mitochondrial dysfunction in SH-SY5Y cells. Acta Biochim Biophys Sin (Shanghai). 2022 Aug 25;54(8):1113-1121. doi: 10.3724/abbs.2022098.
• [51] A MALAT1/HIF-2 feedback loop contributes to arsenite carcinogenesis. Oncotarget. 2016 Feb 2;7(5):5769-87. doi: 10.18632/oncotarget.6806.
• [52] The RNA polymerase III repressor MAF1 is regulated by ubiquitin-dependent proteasome degradation and modulates cancer drug resistance and apoptosis. J Biol Chem. 2019 Dec 13;294(50):19255-19268. doi: 10.1074/jbc.RA119.008849. Epub 2019 Oct 23.
• [53] An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44.
• [54] In vivo chronic exposure to heroin or naltrexone selectively inhibits liver microsome formation of estradiol-3-glucuronide in the rat. Biochem Pharmacol. 2008 Sep 1;76(5):672-9.
• [55] Chronic naltrexone treatment induces desensitization of the luteinizing hormone pulse generator for opioid blockade in hyperprolactinemic patients. J Clin Endocrinol Metab. 1995 May;80(5):1739-42. doi: 10.1210/jcem.80.5.7745028.
• [56] Association between the Stin2 VNTR polymorphism of the serotonin transporter gene and treatment outcome in alcohol-dependent patients. Alcohol Alcohol. 2008 Sep-Oct;43(5):516-22. doi: 10.1093/alcalc/agn048. Epub 2008 Jun 14.
• [57] Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009 Jul;14(3):328-37.